OnKure Therapeutics (NASDAQ:OKUR) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

OnKure Therapeutics (NASDAQ:OKUR) released its quarterly earnings results on Wednesday. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.05, FiscalAI reports.

OnKure Therapeutics Stock Performance

NASDAQ:OKUR traded down $0.07 during mid-day trading on Thursday, reaching $2.52. The stock had a trading volume of 300,237 shares, compared to its average volume of 269,728. The stock has a market capitalization of $102.01 million, a P/E ratio of -0.72 and a beta of 0.18. The firm has a 50 day moving average price of $2.83 and a two-hundred day moving average price of $3.59. OnKure Therapeutics has a one year low of $2.01 and a one year high of $5.38.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on OKUR. Oppenheimer reaffirmed an “outperform” rating and issued a $14.00 target price on shares of OnKure Therapeutics in a research note on Friday, August 14th. HC Wainwright dropped their target price on shares of OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a research report on Monday, July 20th. Finally, Weiss Ratings raised shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $17.50.

About OnKure Therapeutics

OnKure Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company’s research is centered on small-molecule therapies designed to target cancer-driving transcription factors and related proteins that are difficult to address with conventional drug approaches.

Its lead product candidate, OKN4395, is an oral small-molecule inhibitor of the EP300/CBP bromodomains. The program is being investigated as a potential treatment for solid tumors, including in combination with immune checkpoint inhibitors such as pembrolizumab.